LONDON, December 5, 2012 /PRNewswire/ --
- Market demands to reduce manufacturing costs require better Cell culture processes
According to further research conducted for the annual 2013 Cell Line Development & Engineering conference in Vienna next February, major developments in cell culture systems have given biotech's and pharmaceutical companies more flexibility to scale up cells to a high manufacturing quality. Cell engineering tools have enabled the production of high-performing cell lines and this has only been possible through improvements in cell culture media.
To best accommodate for these new developments, Informa Life Sciences' have expanded the programme to cover the latest in cell line development strategies and improvements in cell culture systems. Speaker Alison Porter, Head of Cell Line Development in the Mammalian Cell Culture group at Fujifilm Diosynth Biotechnologies (FFDB) clarifies how '‘With cell line construction on the critical path for first in human studies, it is vital to have optimised the early stages of cell line development. This can improve the future success of a biotherapeutic, both in terms of having the 'best' cell line and meeting increasingly tight timelines.'’
Further feedback from over 50 industry professionals and academics also highlight additional trends such as high throughput screening of cell lines, Quality by Design applications, cell line development strategies for novel products, analytical tools for product evaluation and bioinformatics applications.
Informa's annual 2013 Cell Line Development & Engineering conference has been designed to address topics essential to improve product development and quality. Susanna Benaim Conference Producer at Informa Life Sciences explains "Th
|SOURCE Informa Life Sciences|
Copyright©2012 PR Newswire.
All rights reserved